Overhead view of a doctor looking at his clipboard

Pipeline

Aldeyra Is a Well-Capitalized Biotechonology Company with a Broad Immunology Pipeline

Product CandidatesDisease TargetsPreclinicalPhase 1Phase 2Phase 3NDA Review

Reproxalap

Disease Targets: Dry Eye Disease

Type (ophthalmic solution)

Dry Eye Disease
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

Reproxalap

Disease Targets: Allergic Conjunctivitis

Type (ophthalmic solution)

Allergic Conjunctivitis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Atopic Dermatitis (Part 1)

Type (oral administration)

Atopic Dermatitis (Part 1)
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Chronic Cough

Type (oral administration)

Chronic Cough
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Idiopathic Nephrotic Syndrome (Part 1)

Type (oral administration)

Idiopathic Nephrotic Syndrome (Part 1)
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Sjögren-Larsson Syndrome

Type (oral administration)

Sjögren-Larsson Syndrome
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-629

Disease Targets: Moderate Alcoholic Hepatitis

Type (oral administration)

Moderate Alcoholic Hepatitis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-246

Disease Targets: Systemic Immune-Mediated Diseases

Type (oral administration)

Systemic Immune-Mediated Diseases
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-248

Disease Targets: Geographic Atrophy

Type (intravitreal injection)

Geographic Atrophy
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-2191

(U.S FDA Orphan Drug and Fast Track Designation

Disease Targets: Proliferative Vitreoretinopathy

Type (intravitreal injection)

Proliferative Vitreoretinopathy
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review

ADX-2191

U.S. FDA Orphan-Drug Designation

Disease Targets: Retinitis Pigmentosa

Type (intravitreal injection)

Retinitis Pigmentosa
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review